| Literature DB >> 27015362 |
Juliane Winkler1, Stephanie Roessler1, Carsten Sticht2, Amanda L DiGuilio3, Elisabeth Drucker1, Kerstin Holzer1, Eva Eiteneuer1, Esther Herpel1,4, Kai Breuhahn1, Norbert Gretz2, Peter Schirmacher1, Alessandro Ori5,6, Stephan Singer1,5.
Abstract
Importins and exportins represent an integral part of the nucleocytoplasmic transport machinery with fundamental importance for eukaryotic cell function. A variety of malignancies including hepatocellular carcinoma (HCC) show de-regulation of nuclear transport factors such as overexpression of the exportin Cellular Apoptosis Susceptibility (CAS). The functional implications of CAS in hepatocarcinogenesis remain, however, poorly understood. Here we integrated proteomics, transcriptomics and functional assays with patient data to further characterize the role of CAS in HCC. By analyzing ~ 1700 proteins using quantitative mass spectrometry in HCC cells we found that CAS depletion by RNAi leads to de-regulation of integrins, particularly down-regulation of integrin β1. Consistent with this finding, CAS knockdown resulted in substantially reduced migration and invasion of HCC cell lines as analyzed by 2D 'scratch' and invasion chamber assays, respectively. Supporting the potential in vivo relevance, high expression levels of CAS in HCC tissue samples were associated with macroangioinvasion and poorer patient outcome. Our data suggest a previously unanticipated link between CAS and integrin signaling which correlates with an aggressive HCC phenotype.Entities:
Keywords: CAS; HCC; integrin β1; migration; nuclear transport
Mesh:
Substances:
Year: 2016 PMID: 27015362 PMCID: PMC5008409 DOI: 10.18632/oncotarget.8256
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Figure 1Integrin Δ1 protein and transcript are reduced after CAS silencing
(A) HLE cells were treated either with a control siRNA (ctrl) or a CAS specific siRNA (CAS#2) for 72 h and analyzed by label-free shotgun proteomics. Vulcano plot depicts significance (p-values, -log10, y-axis) and protein fold changes (log2, x-axis) derived from three biological replicates (red: integrin Δ1, green: CAS, orange: integrin αV (upper dot) and integrin α5 (lower dot)) (B) HLE cells were treated as described in (A) either for 24 h or 48 h and subjected to cDNA microarray analyses. Blue and red heat map shows integrins and integrin-associated genes with each replicate relative to the mean expression across all samples. Stars indicate a significant p-value (p ≤ 0.05).
Figure 2CAS is essential for migration of HCC cells in vitro
(A) HLE and HLF cells were treated either with a control siRNA (ctrl) or two CAS specific siRNAs (CAS#1 and CAS#2) and cell extracts were immunoblotted with the indicated antibodies. (B) HLE (left panel) and HLF (right panel) cells were treated as described in (A). 48 h after transfection proliferation was inhibited using mitomycin C and confluent cell monolayer was scratched. Migration was measured by monitoring the closure of the “scratch-wound” using life cell imaging. Time course diagrams show a representative experiment, respectively. (C) Corresponding pictures illustrate the migration assay performed in HLF cells.
Figure 3CAS is essential for invasion of HCC cells in vitro
(A) HLE and (B) HLF cells were treated as described before and invasion through a matrigel coated membrane was analyzed 48 h after transfection. Invaded cells were stained with crystal-violet (right panel) and quantified (left panel). Data are normalized to the ctrl condition and represented as mean of three (A) or two (B) biological replicates ± standard deviation. scale bars = 100 μm.
Figure 4High expression of CAS is associated with poor patient outcome
Shown are (A) CAS and (B) integrin Δ1 (ITGB1) gene expression in HCC (n = 247) compared to non-tumorous liver tissue (n = 239). Differential gene expression of (C) CAS and (D) ITGB1 in HCCs with (n = 31) or without (n = 214) a tumor thrombus in the portal vein. Information on tumor thrombosis was available for 245 patients. (E) Kaplan–Meier plots illustrate 6-year overall survival and (F) disease-free survival over 18 months of low (blue) and high (red) CAS expressing HCC patients. Cutoff value for low and high expression of CAS was the median CAS expression of all patients. Information on overall and disease-free survival were available for 241 and 240 patients, respectively.